Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients

Table 4 Demographics of the 10 patients who developed GnP-induced ILD

	Age	Gender	GnP number of doses	Date of onset	History of lung disease	History of chemotherapy	KL-6 at onset	Treatment	Grade	Concomitant medications	Duration of administration of GJG
1	69	M	11	108	COPD	mFFX 4C	287	mPSL+PSL	3	GJG, RZ	50
2	68	M	28	302	No	No	192	No	1	GJG	134
3	57	F	6	54	No	mFFX 4C	527	No	1	EZ, LP	–
4	79	F	4	43	No	No	3359	No	1	GJG, RZ	43
5	70	M	12	162	No	mFFX 6C	1822	No	1	GJG, RZ	252
6	64	F	6	65	No	No	578	PSL	3	RZ	–
7	72	F	8	80	No	No	6342	mPSL+PSL	3	RZ, LP	–
8	70	M	3	34	No	mFFX 29C	293	mPSL+PSL	2	GJG, RZ	39
9	79	F	8	77	No	No	899	mPSL+PSL	2	GJG, RZ	77
10	65	M	8	139	No	No	409	No	1	GJG, NX, RZ	139

mFFX consists of oxaliplatin 85 mg/m², leucovorin 200 mg/m², irinotecan 150 mg/m², and continuous intravenous infusion of 5-FU at 2400 mg/m², administered every 2 weeks. mPSL was administered at 0.5–1 g/day for 3 days, and PSL was administered at 0.5–1 mg/kg /day and the doses were gradually reduced over the clinical course. GJG was administered at 2.5 g three times daily. RZ was administered at 10 mg once daily. EZ was administered at 20 mg once daily. LP was administered at 60 mg three times daily. NX was administered at 100 mg three times daily
mFFX Modified FOLFIRINOX therapy, mPSL Methylprednisolone, PSL Prednisolone, GJG Goshajinkigan, RZ Rabeprazole Na, EZ Esomeprazole, LP Loxoprofen Na, NX Naproxen

ISSN: 2055-0294